BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Lexington Biosciences Comments on Recent Trading Activity

  On October 17, 2017, the Company’s management became aware of certain promotional materials that were published by Techstock Insider that were purportedly paid for by Ellis Stewart LLC.

  November 1, 2017

   · 

  4 min read
• 

  Deals

  Halyard Health Unloads S&IP Biz to Owens & Minor for $710M

  Shares of Halyard Health are up more than 12 percent after the company announced it was selling its S&IP business to Owens & Minor for $710M.

  November 1, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Big Changes are Coming as Allergan Looks to Cut Costs, Sell Teva Stock

  Allergan released its third-quarter financials, with mixed results and plans to make fairly major changes.

  November 1, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  AstraZeneca’s Asthma Drug Flunks Two Late-Stage Trials

  Astra and its MedImmune division announced that two Phase III clinical trials of tralokinumab for severe, uncontrolled asthma failed to meet their primary endpoints.

  November 1, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Tweaks to bluebird bio’s Gene Therapy Approach May be Working

  Bluebird is making forays into the CAR-T immuno-oncology market, although it has yet to bring a product to market.

  November 1, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  Deals

  Novartis Considers Selling Its $1B+ Dermatology Generics Biz

  Days after plunking down $3.9B+ for AAA, Novartis may be looking to divest itself of its generic dermatology drug business.

  November 1, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Biotech Bay

  Biotechs Salivate as Bay Area VC Firm Banks $419M for Early Life Science R&D

  Frazier announced the closing of a $419M fund aimed solely at the industry.

  November 1, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Biotech Bay

  Bay Area’s AvidBiotics Splits Into Two Biotech Companies

  AvidBiotics is splitting into two separate companies and has developed two separate but similar technology platforms.

  November 1, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Policy

  Top Mylan Exec Targeted in Price-Fixing Suit

  Mylan’s second-ranked exec allegedly took an active role in a vast and “sinister” price-fixing conspiracy among global makers of generic pills.

  November 1, 2017

   · 

  1 min read
• 

  Business

  Secretive Moderna Inks mRNA Heart Failure Deal With AstraZeneca

  The companies will advance the new Relaxin development candidate, AZD7970, toward the clinic as an investigational treatment for heart failure.

  November 1, 2017

   · 

  4 min read